ADCs – Overcoming Analytical Challenges in Next-Gen Cancer Therapeutics
Antibody-Drug Conjugates represent a revolutionary approach in cancer treatment.
This white paper explores the critical analytical challenges in ADC development, focusing on characterization, stability and potency of each ADC component and the need for comprehensive analytical strategies.
This white paper explores the critical analytical challenges in ADC development, focusing on characterization, stability and potency of each ADC component and the need for comprehensive analytical strategies.
Characterizing Each Component
Antibody integrity, linker stability and payload potency each require dedicated analytical methods and control strategies.
Drug-to-Antibody Ratio
DAR distribution drives safety and efficacy. HIC, LC-MS and related techniques provide the resolution needed for control.
Stability and Potency
Stability-indicating methods and cell-based potency assays ensure consistency from development through commercial release.
Download This White Paper
Biotechnology Media Insights
Continue to Biotechnology Media Insights to access this white paper.